Q-omics provides the consensus-scored H1-5 profile across patient tissues and cancer cell-line models. H1-5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, H1-5 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, H1-5 RNA expression shows 19,954 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUAD, and GBM as cancer lineages where H1-5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H1-5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H1-5 survival associations across molecular data types. H1-5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H1-5 RNA expression–survival associations across cancer types. High H1-5 expression shows unfavorable associations in KIRC, ACC, LIHC, LGG and KICH, but favorable associations in CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for H1-5 RNA expression.
This table summarizes H1-5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for H1-5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H1-5 shows higher tumor expression in LUAD, UCEC, HNSC, BRCA, STAD and KIRC. The LUAD box plot shows higher H1-5 RNA expression in tumor versus normal tissue (log2 FC = +0.940, t-test p < 0.001).
This table shows molecular features associated with H1-5 in patient tissues and cancer cell lines. In patient samples, H1-5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, H1-5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
